COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Clin Exp Rheumatol
; 38(2): 337-342, 2020.
Article
in English
| MEDLINE | ID: covidwho-831030
ABSTRACT
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Cytokines
/
Coronavirus Infections
/
Antirheumatic Agents
/
Pandemics
/
Betacoronavirus
/
Anti-Inflammatory Agents
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Clin Exp Rheumatol
Year:
2020
Document Type:
Article
Affiliation country:
Italy
Similar
MEDLINE
...
LILACS
LIS